Citigroup Inc Avrobio, Inc. Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.98 - $1.62 $210 - $348	215 New	215 $0
Q1 2023 May 11, 2023	BUY	$0.76 - $1.82 $14,901 - $35,684	19,607 New	19,607 $19,000
Q3 2022 Nov 10, 2022	SELL	$0.68 - $1.11 $363 - $592	-534 Reduced 50.42%	525 $0
Q2 2022 Aug 10, 2022	SELL	$0.75 - $1.33 $1,139 - $2,020	-1,519 Reduced 58.92%	1,059 $1,000
Q1 2022 May 12, 2022	SELL	$1.29 - $4.04 $10,776 - $33,750	-8,354 Reduced 76.42%	2,578 $3,000
Q4 2021 Feb 10, 2022	SELL	$3.45 - $6.05 $285,411 - $500,504	-82,728 Reduced 88.33%	10,932 $42,000
Q3 2021 Nov 10, 2021	BUY	$5.53 - $9.28 $517,939 - $869,164	93,660 New	93,660 $523,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.